Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.40 |
| ▸ | HTR2B | P41595 | 8/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3019962 | 0.99 | HTR2C (0.40) | HTR2CHTR2BHTR2ASLC6A4HTR6 | |
| Hydrochloric Acid SCHEMBL3019965 | 0.99 | HTR2C (0.40) | HTR2CHTR2BHTR2ASLC6A4HTR6 | |
| Hydrochloric Acid SCHEMBL3019959 | 0.99 | HTR2C (0.40) | HTR2CHTR2BHTR2ASLC6A4HTR6 | |
| SCHEMBL8071399 | 0.81 | HTR2C (0.43) | HTR2CHTR2BHTR2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL3029337 | 0.80 | HTR2C (0.42) | HTR2CHTR2BHTR2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL3029341 | 0.80 | HTR2C (0.42) | HTR2CHTR2BHTR2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL3029339 | 0.80 | HTR2C (0.42) | HTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL8066421 | 0.78 | HTR2C (0.40) | HTR2CHTR2BHTR2ASLC6A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3019629 | 0.77 | HTR2C (0.40) | HTR2CHTR2BHTR2ASLC6A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3019626 | 0.77 | HTR2C (0.40) | HTR2CHTR2BHTR2ASLC6A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| WO-2009037220-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | HTR2C 2/4885HTR2B 15/4885HTR2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.